JP7180977B2 - 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩 - Google Patents

結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩 Download PDF

Info

Publication number
JP7180977B2
JP7180977B2 JP2017539604A JP2017539604A JP7180977B2 JP 7180977 B2 JP7180977 B2 JP 7180977B2 JP 2017539604 A JP2017539604 A JP 2017539604A JP 2017539604 A JP2017539604 A JP 2017539604A JP 7180977 B2 JP7180977 B2 JP 7180977B2
Authority
JP
Japan
Prior art keywords
cancer
malonate
chlorophenyl
isopropylaminopyridin
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017539604A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503650A5 (https=
JP2018503650A (ja
Inventor
ゲイリー デクレッセンゾ，
ディーン ウェルシュ，
ジョン ジー． セルボ，
エカテリーナ ブイ． アルバート，
エミリー エム． リグスビー，
Original Assignee
バイオメッド バレー ディスカバリーズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオメッド バレー ディスカバリーズ，インコーポレイティド filed Critical バイオメッド バレー ディスカバリーズ，インコーポレイティド
Publication of JP2018503650A publication Critical patent/JP2018503650A/ja
Publication of JP2018503650A5 publication Critical patent/JP2018503650A5/ja
Priority to JP2022135858A priority Critical patent/JP7469820B2/ja
Application granted granted Critical
Publication of JP7180977B2 publication Critical patent/JP7180977B2/ja
Priority to JP2024056515A priority patent/JP7701758B2/ja
Priority to JP2025099534A priority patent/JP2025134802A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
JP2017539604A 2015-01-30 2016-01-29 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩 Active JP7180977B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022135858A JP7469820B2 (ja) 2015-01-30 2022-08-29 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
JP2024056515A JP7701758B2 (ja) 2015-01-30 2024-03-29 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
JP2025099534A JP2025134802A (ja) 2015-01-30 2025-06-13 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562110446P 2015-01-30 2015-01-30
US62/110,446 2015-01-30
PCT/US2016/015843 WO2016123581A1 (en) 2015-01-30 2016-01-29 Crystalline c21h22c12n4o2 malonate

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020166896A Division JP2021006560A (ja) 2015-01-30 2020-10-01 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
JP2022135858A Division JP7469820B2 (ja) 2015-01-30 2022-08-29 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩

Publications (3)

Publication Number Publication Date
JP2018503650A JP2018503650A (ja) 2018-02-08
JP2018503650A5 JP2018503650A5 (https=) 2019-03-14
JP7180977B2 true JP7180977B2 (ja) 2022-11-30

Family

ID=56544446

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2017539604A Active JP7180977B2 (ja) 2015-01-30 2016-01-29 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
JP2020166896A Pending JP2021006560A (ja) 2015-01-30 2020-10-01 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
JP2022135858A Active JP7469820B2 (ja) 2015-01-30 2022-08-29 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
JP2024056515A Active JP7701758B2 (ja) 2015-01-30 2024-03-29 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
JP2025099534A Pending JP2025134802A (ja) 2015-01-30 2025-06-13 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020166896A Pending JP2021006560A (ja) 2015-01-30 2020-10-01 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
JP2022135858A Active JP7469820B2 (ja) 2015-01-30 2022-08-29 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
JP2024056515A Active JP7701758B2 (ja) 2015-01-30 2024-03-29 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
JP2025099534A Pending JP2025134802A (ja) 2015-01-30 2025-06-13 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩

Country Status (6)

Country Link
US (2) US9670177B2 (https=)
EP (1) EP3250291B1 (https=)
JP (5) JP7180977B2 (https=)
CA (3) CA3276518A1 (https=)
ES (1) ES2830044T3 (https=)
WO (1) WO2016123581A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
JP7180977B2 (ja) * 2015-01-30 2022-11-30 バイオメッド バレー ディスカバリーズ，インコーポレイティド 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
WO2025264278A1 (en) * 2024-06-18 2025-12-26 Memorial Sloan-Kettering Cancer Center Erk2 degraders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537295A (ja) 2004-05-14 2007-12-20 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｅｒｋプロテインキナーゼのインヒビターとしてのピロール化合物、それらの合成、およびそれらの中間体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599331A (en) 1984-12-24 1986-07-08 Syntex (U.S.A.) Inc. Etianic acids as antiangiogenics
JP2545522B2 (ja) 1985-10-23 1996-10-23 アルコン・ラボラトーリーズ，インコーポレイテッド テトラヒドロ脈管形成抑制ステロイド
US4771042A (en) 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
EP0477195A1 (en) 1989-06-16 1992-04-01 The Upjohn Company Suramin type compounds and angiostatic steroids to inhibit angiogenesis
WO1993010141A2 (en) 1991-11-22 1993-05-27 Alcon Laboratories, Inc. Angiostatic steroids
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7582623B2 (en) 2004-05-20 2009-09-01 The Regents Of The University Of California Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
JP7180977B2 (ja) * 2015-01-30 2022-11-30 バイオメッド バレー ディスカバリーズ，インコーポレイティド 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537295A (ja) 2004-05-14 2007-12-20 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｅｒｋプロテインキナーゼのインヒビターとしてのピロール化合物、それらの合成、およびそれらの中間体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｃ．Ｇ．ＷＥＲＭＵＴＨ編，最新 創薬化学 下巻，株式会社 テクノミック，１９９９年，ｐ．３４７－３６５
小嶌隆史，医薬品開発における結晶形選択の効率化を目指して，薬剤学，２００８年 ９月 １日，Ｖｏｌ．６８、Ｎｏ．５、ｐ．３４４－３４９
平山令明，有機化合物結晶作製ハンドブック，２００８年，ｐ．１７－２３、３７－４０、４５－５１、５７－６５

Also Published As

Publication number Publication date
JP7701758B2 (ja) 2025-07-02
WO2016123581A1 (en) 2016-08-04
ES2830044T3 (es) 2021-06-02
JP7469820B2 (ja) 2024-04-17
JP2025134802A (ja) 2025-09-17
US20160221988A1 (en) 2016-08-04
CA3276518A1 (en) 2025-10-30
US20170320850A1 (en) 2017-11-09
EP3250291A4 (en) 2018-07-18
HK1247584A1 (zh) 2018-09-28
JP2018503650A (ja) 2018-02-08
JP2024081750A (ja) 2024-06-18
CA2975116A1 (en) 2016-08-04
JP2021006560A (ja) 2021-01-21
CA3168216A1 (en) 2016-08-04
CA2975116C (en) 2022-10-11
US9670177B2 (en) 2017-06-06
EP3250291A1 (en) 2017-12-06
JP2022169733A (ja) 2022-11-09
EP3250291B1 (en) 2020-08-26
US9951041B2 (en) 2018-04-24
CA3168216C (en) 2025-11-18

Similar Documents

Publication Publication Date Title
US12187698B2 (en) Crystalline forms of C21H22Cl2N4O2
JP7701758B2 (ja) 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
HK40119285A (en) Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191031

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201001

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201001

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20201009

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20201012

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20201106

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20201110

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220308

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220411

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220829

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220927

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20221021

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20221021

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221117

R150 Certificate of patent or registration of utility model

Ref document number: 7180977

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250